Discovery Laboratories, Inc., a biotechnology company, focuses on developing products for the treatment of respiratory disease. The company’s product pipeline includes Surfaxin, a synthetic, peptide-containing surfactant that has completed Phase-III pivotal trial for the prevention of respiratory distress syndrome (RDS) in premature infants; Surfaxin LS, a lyophilized dosage form of Surfaxin in Phase-III clinical trials, which enhances ease of use for healthcare practitioners; and AEROSURF, a drug-device combination product that has completed first pilot Phase II clinical study of aerosolized KL4 surfactant for the prevention of RDS in premature infants. It has license agreements with Philip Morris USA Inc.; Philip Morris Products S.A.; Johnson & Johnson; and Ortho Pharmaceutical Corporation for its capillary aerosolization and KL4 surfactant technologies. The company also has a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products in Andorra, Greece, Italy, Portugal, and Spain. Discovery Laboratories, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.